Searchable abstracts of presentations at key conferences in oncology

oa0001p011 | (1) | PacRim7

The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer

Chen Julia , Carson Emma , Segara Davendra , Parker Andrew , O'Toole Sandra , Coates Alan , Mann Bruce , Lindeman Geoffrey , Tilley Wayne , Lim Elgene

There is bidirectional interplay between PR and ER in human breast cancers. There is evidence for a reprogramming of ER chromatin binding sites with 470 genes differentially regulated by dual treatment with estrogen plus progestogen compared to estrogen alone in breast cancer cell lines. Functionally, there was an additive anti-cancer effect with the addition of natural progesterone to endocrine therapy in preclinical breast cancer models. This is a phase II multi-site, random...

oa0001p012 | (1) | PacRim7

Targeting AR in endocrine-resistant breast cancer

Chia KeeMing , Milioli Heloisa , Portman Neil , Laven-Law Geraldine , Coulson Rhiannon , Yong Aliza , Segara Davendra , Parker Andrew , Caldon Catherine E , Deng Niantao , Swarbrick Alexander , Tilley Wayne D , Hickey Theresa E , Lim Elgene

Introduction: Resistance to endocrine therapy is a major clinical problem in estrogen receptor positive (ER+) breast cancer. The androgen receptor (AR) is expressed in ~90% of all primary ER+ breast cancers and high expression of AR is associated with a better patient outcome in this tumours. However, uncertainty surrounding the role of AR in endocrine resistance is reflected in current clinical trials in which both AR agonists and antagonists are being investigated. Here, we ...